Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and allow the company to invest more in innovation and margin growth.
Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.
Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.
FRANKLIN LAKES, N.J. (AP) — FRANKLIN LAKES, N.J. (AP) — Becton Dickinson and Co. (BDX) on Wednesday reported fiscal first-quarter earnings of $303 million. On a per-share basis, the Franklin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results